ReviewCancer drug resistance (Alhambra, Calif.)2025

Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression.

Juan Miguel Cejalvo Andújar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.